Molecular Diversity and Antimicrobial Resistance in Clinical Pseudomonas aeruginosa Isolates Associated with Virulence and Biofilm Formation

Haider M. Ali Awad

doi:10.31185/wjps.950

Authors

Haider M. Ali Awad College of Education for Pure Sciences

DOI:

https://doi.org/10.31185/wjps.950

Keywords:

Keywords: nosocomial infection, polymyxin B, multidrug resistance, virulence gene

Abstract

ABSTRACT: Pseudomonas aeruginosa is a dangerous opportunistic pathogen responsible for a share of nosocomial infections that are often fatal with high morbidity. Its bizarre adaptability, inherent mechanisms of resistance, and capability for biofilm formation significantly contribute to its persistence and complicate effective treatment [1, 2]. The study found the prevalence of P. aeruginosa among broad clinical isolates, assessed its biofilm forming capabilities, mapped the distribution of key virulence genes (lasB, toxA, algD, pvdA) and determined its antibiotic susceptibility profiles. Researchers collected 94 proven P. aeruginosa isolates from a range of clinical sources such as respiratory tract infections, burns, wounds, surgical site infections and catheters. Results presented that the isolates had a strong ability to form biofilms, with most of them showing moderate to strong biofilm production. Moreover, a important presence of virulence genes was renowned among the isolates, exactly lasB (86.2%) and toxA (79.8%). Antibiotic susceptibility testing showed diverse levels of resistance, with Cefotaxime (46.7%) and Aztreonam (30.7%) being the maximum resistant. Polymyxin B (4.0%) was still very effective. These results demonstration how complicated P. aeruginosa is as a pathogen and how significant it is to keep an eye on it and come up with new ways to treat it because it is resistant to many drugs.

References

[1] B. Schwartz, K. Klamer, J. Zimmerman, P. B. Kale-Pradhan, and A. Bhargava, “Multidrug resistant Pseudomonas aeruginosa in clinical settings: A review of resistance mechanisms and treatment strategies,” Pathogens, vol. 13, no. 11, p. 975, 2024,. https://doi.org/10.3390/pathogens13110975 DOI: https://doi.org/10.3390/pathogens13110975

[2] S. Qin et al., “Pseudomonas aeruginosa: Pathogenesis, virulence factors, antibiotic resistance, interaction with host, technology advances and emerging therapeutics,” Signal Transduction and Targeted Therapy, vol. 7, no. 1, p. 199, 2022, https://doi.org/10.1038/s41392-022-01056-1 DOI: https://doi.org/10.1038/s41392-022-01056-1

[3] I. Jurado-Martín, M. Sainz-Mejías, and S. McClean, “Pseudomonas aeruginosa: An audacious pathogen with an adaptable arsenal of virulence factors,” International Journal of Molecular Sciences, vol. 22, no. 6, p. 3128, 2021, https://doi.org/10.3390/ijms22063128 DOI: https://doi.org/10.3390/ijms22063128

[4] E. A. Edward, M. R. El Shehawy, A. Abouelfetouh, and E. Aboulmagd, “Prevalence of different virulence factors and their association with antimicrobial resistance among Pseudomonas aeruginosa clinical isolates from Egypt,” BMC Microbiology, vol. 23, no. 1, p. 161, 2023, https://doi.org/10.1186/s12866-023-02897-8 . DOI: https://doi.org/10.1186/s12866-023-02897-8

[5] N. Sathe et al., “Pseudomonas aeruginosa: Infections and novel approaches to treatment,” Infectious Medicine, vol. 2, no. 3, pp. 178–194, 2023, https://doi.org/10.1016/j.imj.2023.05.003 . DOI: https://doi.org/10.1016/j.imj.2023.05.003

[6] R. J. Scheffler, B. P. Bratton, and Z. Gitai, “Pseudomonas aeruginosa clinical blood isolates display significant phenotypic variability,” PLoS ONE, vol. 17, no. 7, p. e0270576, 2022, https://doi.org/10.1371/journal.pone.0270576. DOI: https://doi.org/10.1371/journal.pone.0270576

[7] J. L. D. C. Lima et al., “Analysis of biofilm production by clinical isolates of Pseudomonas aeruginosa from patients with ventilator-associated pneumonia,” Revista Brasileira de Terapia Intensiva, vol. 29, no. 3, pp. 310–316, 2017 https://doi.org/10.5935/0103-507X.20170039 . DOI: https://doi.org/10.5935/0103-507X.20170039

[8] S. A. Howard et al., “Pseudomonas aeruginosa clinical isolates can encode plastic-degrading enzymes that allow survival on plastic and augment biofilm formation,” Cell Reports, vol. 44, no. 5, p. 115650, 2025, https://doi.org/10.1016/j.celrep.2025.115650 . DOI: https://doi.org/10.1016/j.celrep.2025.115650

[9] A. Vetrivel et al., “Pseudomonas aeruginosa biofilm formation and its control,” Biologics, vol. 1, no. 3, pp. 312–336, 2021, https://doi.org/10.3390/biologics1030019 . DOI: https://doi.org/10.3390/biologics1030019

[10] A. J. Jasem and M. A. Mahmood, “Development and characterization of chitosan nanoparticles loaded with amoxicillin as advanced drug delivery systems against Streptococcus mutans,” IHJPAS, vol. 38, no. 1, pp. 1–15, 2025, https://doi.org/10.30526/38.1.3501 .

[11] C. O. Ezeador, P. C. Ejikeugwu, S. N. Ushie, and N. R. Agbakoba, “Isolation, identification and prevalence of Pseudomonas aeruginosa isolates from clinical and environmental sources in Onitsha metropolis,” European Journal of Medical and Health Sciences, vol. 2, no. 2, 2020, https://doi.org/10.24018/EJMED.2020.2.2.188 . DOI: https://doi.org/10.24018/ejmed.2020.2.2.188

[12] Clinical and Laboratory Standards Institute, Performance Standards for Antimicrobial Susceptibility Testing, 35th ed., CLSI supplement M100. Wayne, PA, USA: CLSI, 2025.

[13] A. A. Elmanama, R. I. Abu-Dan, and S. Al-Sheboul, “Biofilm and antimicrobial resistance of clinical and environmental isolates of Pseudomonas aeruginosa,” Isra University Journal of Applied Sciences, vol. 6, no. 1, pp. 174–190, 2022, https://doi.org/10.52865/zmqq2426 DOI: https://doi.org/10.52865/ZMQQ2426

[14] P. Behzadi et al., “Relationship between biofilm-formation, phenotypic virulence factors and antibiotic resistance in environmental Pseudomonas aeruginosa,” Pathogens, vol. 11, no. 9, p. 1015, 2022 https://doi.org/10.3390/pathogens11091015 , . DOI: https://doi.org/10.3390/pathogens11091015

[15] Farzin Asghari-Sana, S. Ahmadi Asli, and S. Golbouy Daghdari, “Biofilm formation, pigment production, and virulence gene profiles in Pseudomonas aeruginosa isolates from respiratory and urinary tract infections,” Gene Reports, vol. 39, p. 102184, 2025, https://doi.org/10.1016/j.genrep.2025.102184. DOI: https://doi.org/10.1016/j.genrep.2025.102184

[16] C. Elmouaden et al., “Virulence genes and antibiotic resistance of Pseudomonas aeruginosa isolated from patients in Northwestern Morocco,” Journal of Infection in Developing Countries, vol. 25, no. 1, pp. 45–52, 2019 ,. https://doi.org/10.3855/jidc.10675 DOI: https://doi.org/10.3855/jidc.10675

[17] T. Spilker, T. Coenye, P. Vandamme, and J. J. LiPuma, “PCR-based assay for differentiation of Pseudomonas aeruginosa from other Pseudomonas species,” Journal of Clinical Microbiology, vol. 42, no. 5, pp. 2074–2079, 2004, https://doi.org/10.1128/JCM.42.5.2074-2079.2004 DOI: https://doi.org/10.1128/JCM.42.5.2074-2079.2004

[18] V. S. Nikbin et al., “Molecular identification and detection of virulence genes among Pseudomonas aeruginosa isolated from different infectious origins,” Iranian Journal of Microbiology, vol. 4, no. 3, pp. 118–123, 2012.

[19] A. A. Khan and C. E. Cerniglia, “Detection of Pseudomonas aeruginosa by amplification of the exotoxin A gene,” Applied and Environmental Microbiology, vol. 60, no. 10, pp. 3739–3745, 1994, https://doi.org/10.1128/aem.60.10.3739-3745.1994. DOI: https://doi.org/10.1128/aem.60.10.3739-3745.1994

[20] S. Mohammadi Baladezaee et al., “Molecular investigation of LasA, LasB, and PIV genes in Pseudomonas aeruginosa,” Folia Medica, vol. 66, no. 3, pp. 361–369, 2024, https://doi.org/10.3897/folmed.66.e124561 DOI: https://doi.org/10.3897/folmed.66.e124561

[21] H. O. M. Al-Dahmoshi, “Genotypic and phenotypic investigation of alginate biofilm formation among Pseudomonas aeruginosa isolated from burn victims,” Babylon, Iraq, 2013.

[22] F. Ali et al., “Antimicrobial resistance pattern and phenotypic detection of ESBL- and MBL-producing Pseudomonas aeruginosa,” Kuwait Journal of Science, 2022, https://doi.org/10.48129/kjs.10773 . DOI: https://doi.org/10.48129/kjs.10773

[23] I. J. Schalk and Q. Perraud, “Pseudomonas aeruginosa and its multiple strategies to access iron,” Environmental Microbiology, vol. 25, no. 4, pp. 811–831, 2023, https://doi.org/10.1111/1462-2920.16328 . DOI: https://doi.org/10.1111/1462-2920.16328

[24] F. Minandri et al., “Role of iron uptake systems in Pseudomonas aeruginosa virulence,” Infection and Immunity, vol. 84, no. 8, pp. 2324–2335, 2016, https://doi.org/10.1128/IAI.00098-16. DOI: https://doi.org/10.1128/IAI.00098-16

[25] N. Pájaro-Castro et al., “Whole-genome sequencing of resistance and virulence genes in Pseudomonas aeruginosa,” Medical Sciences, vol. 13, no. 1, p. 6, 2025 https://doi.org/10.3390/medsci13010006 , DOI: https://doi.org/10.3390/medsci13010006

[26] A. Silva et al., “Antimicrobial resistance, genetic lineages, and biofilm formation in Pseudomonas aeruginosa,” Antibiotics, vol. 12, 2023 https://doi.org/10.3390/antibiotics12081248, DOI: https://doi.org/10.3390/antibiotics12081248

[27] K. Pokharel, B. R. Dawadi, and L. B. Shrestha, “Role of biofilm in bacterial infection and antimicrobial resistance,” JNMA Journal of Nepal Medical Association, vol. 60, no. 253, pp. 836–840, 2022, https://doi.org/10.31729/jnma.7580 DOI: https://doi.org/10.31729/jnma.7580

[28] N. M. Maurice, B. Bedi, and R. T. Sadikot, “Pseudomonas aeruginosa biofilms: Host response and clinical implications in lung infections,” Am. J. Respir. Cell Mol. Biol., vol. 58, no. 4, pp. 428–439, 2018, DOI: https://doi.org/10.1165/rcmb.2017-0321TR

https://doi.org/10.1165/rcmb.2017-0326TR